Suppression by nimesulide of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats

Clinical and Experimental Metastasis

Volumn 20, Issue 6, 2003, Pages 555-560

  Iishi, Hiroyasu ^a   Tatsuta, Masaharu ^a   Baba, Miyako ^a   Yano, Hiroyuki ^a   Higashino, Koji ^a   Mukai, Mutsuko ^a   Akedo, Hitoshi ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Azoxymethane; Intestinal cancer; Matrix metalloproteinase; Metastasis; Nimesulide; Rat

Indexed keywords

ANTIMETASTATIC AGENT; AZOXYMETHANE; BOMBESIN; CYCLOOXYGENASE 2 INHIBITOR; GELATINASE B; NIMESULIDE;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER LOCALIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HISTOPATHOLOGY; INTESTINE CARCINOMA; LYMPHATIC SYSTEM DISEASE; MALE; METASTASIS INHIBITION; NONHUMAN; PERITONEUM METASTASIS; RAT;

ADENOCARCINOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZOXYMETHANE; BOMBESIN; CARCINOGENS; DISEASE MODELS, ANIMAL; INTESTINAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PERITONEAL NEOPLASMS; RATS; RATS, WISTAR; SULFONAMIDES;

EID: 0142061977     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025883129932     Document Type: Article

References (25)

1. Thun MJ, Namboodiri MM, Heath CWJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
2. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89.
3. Thun MJ, Namboodiri MM, Calle EE et al. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-7.
4. Giovannucci E, Rimm EB, Stampfer MJ et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6.
5. Marnett LJ. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prev Med 1995; 24: 103-6.
6. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer and development. Oncogene 1999; 18: 7908-16.
7. Tsujii M, DuBois RN. Alternations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
8. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-40.
9. Iishi H, Tatsuta M, Baba M et al. Enhancement by bombesin of colon carcinogenesis and metastasis induced by azoxymethane in Wistar rats. Int J Cancer 1992; 50: 834-9.
10. Iishi H, Tatsuta M, Baba M et al. Ornithine decarboxylase inhibitor attenuates bombesin enhancement of intestinal carcinogenesis and metastasis induced by azoxymethane. Int J Cancer 1994; 58: 533-7.
11. Japanese Research Society for Cancer of the Colon and Rectum. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus, 6th edition. Tokyo: Kanehara Shoten 1998.
12. Nagatsuka I, Yamada N, Shimizu S et al. Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer. Int J Cancer 2002; 100: 515-9.
13. Siegel S. Nonparametric Statistics for the Behavioral Sciences. New York: McGraw-Hill 1956.
14. Tomozawa S, Nagawa H, Tsuno N et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 1999; 81: 1274-9.
15. Chen WS, Wei SJ, Liu JM et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selectieve, etodolac. Int J Cancer 2001; 91; 894-9.
16. Kundu N, Fulton AM. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002; 62: 2343-6.
17. Yao M, Kargman S, Lam EC et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003; 63: 586-92.
18. Pan MR, Chuang LY, Hung WC. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett 2001; 508: 365-8.
19. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001; 93: 497-506.
20. Kozaki K, Miyaishi O, Tsukamoto T et al. Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res 2000; 69: 2535-40.
21. Iishi H, Tatsuta M, Baba Y et al. Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Chemotherapy 2001; 47: 70-6.
22. Attiga FA, Fernadez PM, Weeraratna AT et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000; 60: 4629-37.
23. Callejas NA, Casado M, Diaz-Guerra MJ et al. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinases-2 and -9 in fetal rat hepatocytes. Hepatology 2001; 33: 860-7.
24. Jiang MC, Liao CF, Lee PH. Aspirin inhibits matrix metalloproteinase activity, increases E-cadherin production and inhibits in vitro invasion of tumor. Biochem Biophys Res Commun 2001; 282: 671-7.
25. Murata H, Kawano S, Tsuji S et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinomas. Am J Gastroenterol 1999; 94: 451-5.